Ritsa Pharma Profile
Key Indicators
- Authorised Capital ₹ 30.00 Cr
as on 28-10-2024
- Paid Up Capital ₹ 10.00 Cr
as on 28-10-2024
- Company Age 4 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.52 Cr
as on 28-10-2024
- Revenue %
(FY 2023)
- Profit -93.29%
(FY 2023)
- Ebitda -76.54%
(FY 2023)
- Net Worth -4182.62%
(FY 2023)
- Total Assets 18.82%
(FY 2023)
About Ritsa Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 30.00 Cr and a paid-up capital of Rs 10.00 Cr.
The company currently has active open charges totaling ₹4.52 Cr.
Ganji Kumar, Narendra Vutla, Venkateswara Yarlagadda, and Three other members serve as directors at the Company.
- CIN/LLPIN
U24290TG2020PTC145093
- Company No.
145093
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Oct 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Ritsa Pharma?
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ganji Kumar  | Director | 21-Oct-2020 | Current |
| Narendra Vutla | Director | 07-Jul-2023 | Current |
| Venkateswara Yarlagadda | Director | 21-Oct-2021 | Current |
| Srilalitha Bhattaram | Director | 24-Feb-2021 | Current |
| Manaswini Vemulapalli | Nominee Director | 09-Aug-2021 | Current |
| Chandrasekhar Penugonda | Additional Director | 11-Jun-2024 | Current |
Financial Performance and Corporate Structure Insights of Ritsa Pharma.
Ritsa Pharma Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 93.29% decrease in profit. The company's net worth observed a substantial decline by a decrease of 4182.62%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ritsa Pharma?
In 2023, Ritsa Pharma had a public holding of 50.33%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Hyderabad Angels Forum For Entrepreneurship DevelopmentActive 12 years 5 monthsGanji Kumar is a mutual person
Airis Pharma Private LimitedActive 11 years 4 monthsGanji Kumar and Srilalitha Bhattaram are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 21 Nov 2023 | ₹4.52 Cr | Open |
How Many Employees Work at Ritsa Pharma?
Unlock and access historical data on people associated with Ritsa Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ritsa Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ritsa Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
